What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
His primary areas of study are Cancer research, Imatinib mesylate, Imatinib, Chronic myelogenous leukemia and Leukemia.
His Cancer research research incorporates themes from Mutation, Tyrosine kinase, Proto-oncogene tyrosine-protein kinase Src, Receptor tyrosine kinase and K562 cells.
He has researched Imatinib mesylate in several fields, including Cytarabine and ABL.
His Imatinib study is concerned with Myeloid leukemia in general.
His study on Chronic myelogenous leukemia also encompasses disciplines like
- Philadelphia chromosome together with Drug resistance,
- Clinical trial that connect with fields like Pharmacology.
His Leukemia research is multidisciplinary, incorporating elements of Myeloid, Regulation of gene expression and Pharmacokinetics.
His most cited work include:
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia (4424 citations)
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (3544 citations)
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. (3161 citations)
What are the main themes of his work throughout his whole career to date?
Brian J. Druker spends much of his time researching Cancer research, Myeloid leukemia, Imatinib, Leukemia and Imatinib mesylate.
His research integrates issues of Tyrosine kinase, ABL, Chronic myelogenous leukemia, Philadelphia chromosome and Kinase in his study of Cancer research.
His Myeloid leukemia study combines topics from a wide range of disciplines, such as Myeloid and Progenitor cell, Stem cell.
His Imatinib research integrates issues from Oncology, Tyrosine-kinase inhibitor and Pharmacology.
His Leukemia research focuses on Bone marrow and how it relates to Stromal cell.
His Imatinib mesylate study frequently links to related topics such as Signal transduction.
He most often published in these fields:
- Cancer research (72.38%)
- Myeloid leukemia (42.82%)
- Imatinib (37.88%)
What were the highlights of his more recent work (between 2016-2021)?
- Cancer research (72.38%)
- Myeloid leukemia (42.82%)
- Leukemia (40.29%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Cancer research, Myeloid leukemia, Leukemia, Internal medicine and Cancer.
Brian J. Druker does research in Cancer research, focusing on Imatinib mesylate specifically.
His biological study spans a wide range of topics, including Ponatinib and ABL.
Brian J. Druker works in the field of Myeloid leukemia, focusing on Imatinib in particular.
His work in Leukemia addresses issues such as Bone marrow, which are connected to fields such as Stromal cell and Tumor microenvironment.
While the research belongs to areas of Internal medicine, Brian J. Druker spends his time largely on the problem of Oncology, intersecting his research to questions surrounding Tyrosine-kinase inhibitor, Survival analysis and BET inhibitor.
Between 2016 and 2021, his most popular works were:
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (434 citations)
- Functional genomic landscape of acute myeloid leukaemia. (288 citations)
- Functional genomic landscape of acute myeloid leukaemia. (288 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Brian J. Druker mostly deals with Cancer research, Leukemia, Myeloid leukemia, Myeloid and Internal medicine.
His work carried out in the field of Cancer research brings together such families of science as Viability assay, Cell, Cell culture, Kinase and Allosteric regulation.
His studies in Leukemia integrate themes in fields like Atypical chronic myeloid leukemia, Ruxolitinib and Tyrosine-kinase inhibitor.
Specifically, his work in Myeloid leukemia is concerned with the study of Imatinib.
He studies Imatinib, namely Imatinib mesylate.
His Internal medicine study which covers Oncology that intersects with Survival analysis, Clinical trial and Precision medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
